Two Sigma Advisers LP Raises Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Two Sigma Advisers LP increased its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 4.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 333,400 shares of the company’s stock after purchasing an additional 15,400 shares during the quarter. Two Sigma Advisers LP’s holdings in Autolus Therapeutics were worth $783,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Two Sigma Investments LP boosted its stake in shares of Autolus Therapeutics by 23.8% during the 4th quarter. Two Sigma Investments LP now owns 906,767 shares of the company’s stock worth $2,131,000 after purchasing an additional 174,485 shares during the period. TFG Asset Management GP Ltd boosted its stake in shares of Autolus Therapeutics by 3.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company’s stock worth $19,388,000 after purchasing an additional 250,000 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Autolus Therapeutics during the 4th quarter worth about $581,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Autolus Therapeutics during the 4th quarter worth about $85,000. Finally, Millennium Management LLC boosted its stake in shares of Autolus Therapeutics by 91.6% during the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company’s stock worth $3,885,000 after purchasing an additional 790,437 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL opened at $1.91 on Tuesday. Autolus Therapeutics plc has a one year low of $1.11 and a one year high of $5.00. The firm has a market cap of $508.33 million, a P/E ratio of -1.58 and a beta of 1.77. The firm has a 50-day simple moving average of $1.42 and a 200-day simple moving average of $1.99.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. On average, research analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Truist Financial lowered their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Finally, Wells Fargo & Company lowered their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday, March 21st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.